800 related articles for article (PubMed ID: 24913977)
1. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
[TBL] [Abstract][Full Text] [Related]
2. Targeted Co-delivery of Tumor Antigen and α-Galactosylceramide to CD141
Huang J; Zhou J; Ghinnagow R; Seki T; Iketani S; Soulard D; Paczkowski P; Tsuji Y; MacKay S; Cruz LJ; Trottein F; Tsuji M
Front Immunol; 2020; 11():2043. PubMed ID: 32973811
[TBL] [Abstract][Full Text] [Related]
3. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
Hermans IF; Silk JD; Gileadi U; Salio M; Mathew B; Ritter G; Schmidt R; Harris AL; Old L; Cerundolo V
J Immunol; 2003 Nov; 171(10):5140-7. PubMed ID: 14607913
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cell internalization of α-galactosylceramide from CD8 T cells induces potent antitumor CD8 T-cell responses.
Choi DH; Kim KS; Yang SH; Chung DH; Song B; Sprent J; Cho JH; Sung YC
Cancer Res; 2011 Dec; 71(24):7442-51. PubMed ID: 22028323
[TBL] [Abstract][Full Text] [Related]
5. NKT Cell-Driven Enhancement of Antitumor Immunity Induced by Clec9a-Targeted Tailorable Nanoemulsion.
Lam PY; Kobayashi T; Soon M; Zeng B; Dolcetti R; Leggatt G; Thomas R; Mattarollo SR
Cancer Immunol Res; 2019 Jun; 7(6):952-962. PubMed ID: 31053598
[TBL] [Abstract][Full Text] [Related]
6. Suppression of murine tumour growth through CD8
Kogo H; Shimizu M; Negishi Y; Uchida E; Takahashi H
Immunology; 2017 Jul; 151(3):324-339. PubMed ID: 28294313
[TBL] [Abstract][Full Text] [Related]
7. Langerin+ CD8alpha+ dendritic cells are critical for cross-priming and IL-12 production in response to systemic antigens.
Farrand KJ; Dickgreber N; Stoitzner P; Ronchese F; Petersen TR; Hermans IF
J Immunol; 2009 Dec; 183(12):7732-42. PubMed ID: 19923446
[TBL] [Abstract][Full Text] [Related]
8. Role of γδ T cells in α-galactosylceramide-mediated immunity.
Paget C; Chow MT; Duret H; Mattarollo SR; Smyth MJ
J Immunol; 2012 Apr; 188(8):3928-39. PubMed ID: 22412194
[TBL] [Abstract][Full Text] [Related]
9. Activation of invariant Natural Killer T lymphocytes in response to the α-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles.
Macho Fernandez E; Chang J; Fontaine J; Bialecki E; Rodriguez F; Werkmeister E; Krieger V; Ehret C; Heurtault B; Fournel S; Frisch B; Betbeder D; Faveeuw C; Trottein F
Int J Pharm; 2012 Feb; 423(1):45-54. PubMed ID: 21575695
[TBL] [Abstract][Full Text] [Related]
10. Miscarriage induced by adoptive transfer of dendritic cells and invariant natural killer T cells into mice.
Negishi Y; Ichikawa T; Takeshita T; Takahashi H
Eur J Immunol; 2018 Jun; 48(6):937-949. PubMed ID: 29520760
[TBL] [Abstract][Full Text] [Related]
11. Administration of alpha-galactosylceramide impairs the survival of dendritic cell subpopulations in vivo.
Simkins HM; Hyde E; Farrand KJ; Ong ML; Degli-Esposti MA; Hermans IF; Ronchese F
J Leukoc Biol; 2011 May; 89(5):753-62. PubMed ID: 21297009
[TBL] [Abstract][Full Text] [Related]
12. Invariant NKT cells preferentially modulate the function of CD8 alpha+ dendritic cell subset in inducing type 1 immunity against infection.
Joyee AG; Uzonna J; Yang X
J Immunol; 2010 Feb; 184(4):2095-106. PubMed ID: 20089704
[TBL] [Abstract][Full Text] [Related]
13. Synergistic induction of adaptive antitumor immunity by codelivery of antigen with α-galactosylceramide on exosomes.
Gehrmann U; Hiltbrunner S; Georgoudaki AM; Karlsson MC; Näslund TI; Gabrielsson S
Cancer Res; 2013 Jul; 73(13):3865-76. PubMed ID: 23658368
[TBL] [Abstract][Full Text] [Related]
14. Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice.
Shimizu K; Goto A; Fukui M; Taniguchi M; Fujii S
J Immunol; 2007 Mar; 178(5):2853-61. PubMed ID: 17312129
[TBL] [Abstract][Full Text] [Related]
15. In vivo and in vitro analyses of α-galactosylceramide uptake by conventional dendritic cell subsets using its fluorescence-labeled derivative.
Ushida M; Iyoda T; Kanamori M; Watarai H; Takahara K; Inaba K
Immunol Lett; 2015 Dec; 168(2):300-5. PubMed ID: 26481266
[TBL] [Abstract][Full Text] [Related]
16. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
Fujii S; Shimizu K; Hemmi H; Steinman RM
Immunol Rev; 2007 Dec; 220():183-98. PubMed ID: 17979847
[TBL] [Abstract][Full Text] [Related]
17. Activated iNKT cells promote Vγ9Vδ2-T cell anti-tumor effector functions through the production of TNF-α.
Schneiders FL; de Bruin RC; Santegoets SJ; Bonneville M; Scotet E; Scheper RJ; Verheul HM; de Gruijl TD; van der Vliet HJ
Clin Immunol; 2012 Feb; 142(2):194-200. PubMed ID: 22122798
[TBL] [Abstract][Full Text] [Related]
18. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
[TBL] [Abstract][Full Text] [Related]
19. Mediastinal lymph node CD8alpha- DC initiate antigen presentation following intranasal coadministration of alpha-GalCer.
Ko SY; Lee KA; Youn HJ; Kim YJ; Ko HJ; Heo TH; Kweon MN; Kang CY
Eur J Immunol; 2007 Aug; 37(8):2127-37. PubMed ID: 17615581
[TBL] [Abstract][Full Text] [Related]
20. Potent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand.
Petersen TR; Sika-Paotonu D; Knight DA; Dickgreber N; Farrand KJ; Ronchese F; Hermans IF
Immunol Cell Biol; 2010 Jul; 88(5):596-604. PubMed ID: 20142835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]